Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

171 results about "Β glucosidase" patented technology

Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy

ActiveUS20060166277A1Diagnosing and effectively treatingSave maternalMicrobiological testing/measurementDisease diagnosisPregnancyUdp glycosyltransferase
Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC

Nutritional and safe soy milk making method of soy milk maker

The invention relates to a nutritional and safe soy milk making method of a soy milk maker, and aims at the problems that for a traditional view, water for soaking soybeans is not suitable for soy milk preparation, and dissolving-out condition of a functional component during soy milk making is almost ignored in the prior art. A main functional component soy isoflavone in soybeans plays an important role in the aspects of prevention and treatment for breast cancer and prostate cancer, improvement of climacteric syndrome and osteoporosis, protection for a cardiovascular system and the like. In order to change the misconception and obtain higher-content and high-activity isoflavone soybean milk to improve nutritive values of the soy milk, the soybeans are heated, sterilized and soaked for a long time before soy milk making, after the soybeans are soaked with the method, malignant bacteria in water can be effectively killed, and water for soaking the soybeans can be used for soy milk making; and besides, the activity of beta glucosaccharase in the soybeans can be maintained, glucosidic isoflavone hard to be absorbed by a human body is hydrolyzed into aglycone isoflavone, so that isoflavone in the soybeans are sufficiently released, and a better healthcare effect can be provided for consumers.
Owner:JOYOUNG CO LTD

5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia

The present invention relates to certain pyrazole carboxylic acid derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, as antilipolytic agents and against for the receptor RUP25, wherein: R2 is H, halogen, C1-12 alkyl or C1-12 haloalkyl; and R3 is C3-6 cycloalkyl, C1-12 alkyl, C1-12 haloalkyl, C3-6 cycloalkyl-C1-4-alkylene, aryl-C1-4-alkylene or heteroaryl-C1-4-alkylene, wherein said aryl-C1-4-alkylene and heteroaryl-C1-4-alkylene can be optionally substituted 1 to 5 substituents selected from the substituents listed in the claims. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for pharmaceutical compositions in combination with other active agents, for example, those agents belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like.
Owner:ARENA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products